Graft-versus-host-disease (GvHD) is the main complication of allogeneic hematopoietic stem cell 39 transplantation. GvHD patients have aberrant T cell expansions, which are thought to drive pathological 40 immune activation. Here we report mechanistic insights that somatic mutations may account for persistent 41 clonal T cell expansions in chronic GvHD (cGvHD). In an index patient suffering from cGVHD, we discovered 42 persisting somatic MTOR, NFKB2, and TLR2 mutations in an expanded CD4+ T clone. In the screening 43 cohort (n=135), the MTOR P2229R kinase domain mutation was detected in two additional cGvHD patients, 44
abnormal proliferation of the clonally expanded CD4+ T cells. Real-time impedance measurements 48 indicated increased cytotoxicity of mutated CD4 + T cells against the patient´s fibroblasts. High throughput 49 drug-sensitivity testing suggested that mutations induce resistance to mTOR inhibitors but increase 50 sensitivity for HSP90 inhibitors. Our findings suggest a novel explanation for the aberrant, persistent T cell 51 activation in cGvHD, and pave the way for novel targeted therapies. 52 53 INTRODUCTION immunosuppressive therapy were evaluated in vitro, and finally verified with patient cells using drug 78 sensitivity screening and unbiased transcriptome-wide single-cell RNA-sequencing (scRNA-seq) paired with 79 T cell receptor alpha and beta sequencing (TCRab-seq) analysis and functional cytotoxicity assays. 80 81 memory (CM) cells (6.2%) when compared with the sibling donor's CD4+ T cell pool (59.6% EM, 5.0% 106 TEMRA, and 19.9% CM cells)( Figure 1D ). In the CD8+ T cell pool, increased amount of TEMRA cells was 107 noted (79.9% of CD8+ T cells). 108 109
Somatic Mutations in the Expanded CD4+ T Cell Population of the Index Patient 110
To screen for somatic mutations, a customized immunity and inflammation-related gene sequencing panel 111 (immunogene panel)(6) was applied to immunomagnetic bead-separated blood CD4+ and CD8+ T cells, that 112 were obtained from the index patient in 2013. The median target gene coverage for the panel was 152 in 113 CD4+ and 160 for CD8+ T cells. In total, 14 candidate putative somatic mutations were discovered within 114 the CD4+ T cells (Table 1) , and one in CD8+ cells ( Table S7A in the Supplementary Appendix). Based on the 115 known biological significance, three of the mutations (MTOR, NFkB2, and TLR2) were considered as 116 putative driver mutations and potentially important for disease pathogenesis and were studied further. 117
The previously undescribed somatic missense mutation in MTOR (position 11182160, G to C) changes the 118 amino acid proline 2229 to arginine (Figure 2A ). The variant allele frequency (VAF) was 13.3% among 119
CD4+T cells (Table 1) . This mutation in exon 48 is located in the kinase domain which has been suggested to 120 be important for signal transduction.(7) In addition to MTOR, two other interesting mutations were 121 identified in the NFkB2 and TLR2 genes, although these were statistically not significant (p>0.01) due to the 122 low coverage in these locations (Table 1 ). The NFkB2 missense mutation (position 104162075, C to A) leads 123 to a change of the amino acid proline 882 to glutamine (Figure 2A ). TLR2 missense mutation (position 124 154625732, G to T) results in a change of the amino acid tryptophan 558 to leucine (Figure 2A ). The 125 transcription factor NFkB2 is a critical regulator of inflammation and immune function.(8) Toll-like-receptor 126 2 (TLR2) is one of the pattern recognition receptors and has been shown to be a crucial player for the 127 pathogenesis of autoimmune diseases. Notably, TLR2 protein has been shown to be highly expressed in 128
GvHD patients.(9) 129 100.000X and a sensitivity of 0.5% VAF(10) was applied to all available samples from different time points 140 to establish the dynamics and the lineage specificity of the discovered mutations. The MTOR mutation was 141 detected in CD4+ T cells that were obtained in 2015 and 2017 with VAFs 19.2 % and 21.0 %, respectively 142 (Table 2 and Table S7 in the Supplementary Appendix). The VAF of the MTOR mutation appeared to 143 increase from 2013 to 2017 regardless of the continuous immunosuppressive therapy ( Figure 2C ). No 144 mutations or very low VAFs were detected within flow-sorted CD3-, CD8+/CD4-, CD4+Vβ20-, CD4+CD8+ 145 Vβ20-, and monocyte samples ( Figure S2C and Table S8 in the Supplementary Appendix). Thus, the 146 mutation was confined to the CD4+ Vβ20+ cell fraction (VAF 44.7% in flow-sorted cells). 147
Similarly, the NFkB2 P882Q mutation was confirmed to be limited to CD4+Vβ20+ T cells (VAFs: 12.0% in 148 CD4+ T cells and 21.3% in CD4+Vβ20+ cells) (Table 2, S7 and S8 in the Supplementary Appendix). In 149 contrast, TLR2 W558L mutation was discovered in both CD4+ (VAFs: 16.5% in CD4+ cells, 35.5% in 150
CD4+Vβ20+ cells) and CD8+ T cells (VAF 4.7 %) (Table S9 and S10 in Supplementary Appendix). 151
152
In the course of the disease, the cGvHD affected different organs of the index patient, but particularly the 153 skin. To explore whether lymphocytes harboring the detected somatic mutations can be found in target 154 organs, we screened paraffin-embedded biopsy samples by amplicon sequencing. The MTOR mutation was 155 identified in a sclerodermatous lesion that was biopsied in 2015 (VAF 0.8 %), but not in eye or liver biopsies 156 (Table 2) . Immunofluorescence staining demonstrated CD4+ and CD8+ T cell infiltration in the same 157 sclerodermatous lesion ( Figure 2D ). 158
To examine whether the mutations were already present in the donor, both CD4+ and CD8+ T cells from 159 the donor were sequenced by amplicon sequencing, but no mutations were detected. 160 161
Screening for the Identified MTOR, TLR2, and NFkB2 Mutations in cGvHD patient Cohort 162
To explore whether the found mutations are recurrent, blood samples from 135 cGvHD patients, 38 allo-163 HSCT patients without cGvHD, and 54 healthy controls were screened by the amplicon sequencing. Two 164 additional cGvHD patients carried the same MTOR missense mutation yielding in a MTOR P2229R mutation 165 frequency of 2.2 % in all cGvHD patients (3 out of 135). In healthy controls or allo-HSCT patients without 166 cGvHD, no MTOR mutations were detected. Furthermore, NFkB2 mutations were neither detected in 167 additional cGvHD patients nor in controls. The TLR2 W558L mutation was found in both cGvHD patients 168 and healthy controls, but the VAF indicated a 10-and 4-fold higher mutation frequency in cGvHD patients' 169 CD4+ and CD8+ T cells compared to healthy controls ( Figure S3 , Tables S9 and S10 in the Supplementary 170 Appendix). 171 172
Identified Somatic Mutations Result in a Gain-of-function Alteration 173
MTOR consists of two functionally distinct multi-protein complexes, mTORC1 and mTORC2. Eukaryotic 174 translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) and ribosomal S6 kinase (S6K1) are among 175
the key substrates of mTORC1, and as such critical regulators of cap-dependent translation.(11)mTORC2 176 directly phosphorylates AKT, thereby promoting cell survival.(12) Various genomic alterations have been 177 shown to aberrantly activate the mTOR pathways(13), which is marked by an increased phosphorylation of 178 downstream factors, such as S6K1, S6, and AKT. To examine the functional consequences of the MTOR 179 P2229R and other mutations, we transduced HEK293 human embryonic kidney cells with mutant 180 constructs. Both the MTOR P2229R single mutant and triple mutant resulted in a substantially enhanced 181 phosphorylation of S6K1, S6, and AKT compared to wild-type (WT) MTOR or triple WT ( Figures 3A and B ) 182
suggesting an activation of both mTORC1 and mTORC2 pathways. 183
The NFkB2 P882Q mutation is located in the c-terminal domain (Figure 2A ), which is known to play an 184 important role in the ubiquitination and partial proteolysis from NFkB2 (p100) to NFkB2 (p52).(14) In order 185 to determine the molecular balance between these two states, we performed immunoblotting which 186 revealed an increased expression of p52 ( Figures 3C and D) indicating a gain-of-function alteration. 187
Similarly, to study the functional consequences of the TLR2 W558L mutation, we evaluated alterations in 188 transcriptional regulation by analyzing mRNA expression levels of a subset of TLR2 downstream targets by 189
qRT-PCR. This demonstrated significantly increased expression levels of ELK1 and FOS1 in the TLR2 W558L 190 mutant expressing cell line as compared to the WT control ( Figure S4B in the Supplementary Appendix). 191
192

Paired scRNA-and TCRab sequencing of the CD4+ T cells from the index patient from two time points 193
Recently, entire transcriptome at the single-cell level has been explosively studied for revealing a 194 differential gene expression profiles between individual cells, which cannot be identified from analysis of 195 mixed cells. (15) 196 In order to better understand the heterogeneity of the clonotype and the underlying CD4+ T cell 197 compartment in an unbiased manner, we performed simultaneous single-cell RNA and paired TCRab 198 sequencing on two time points in 2015 and 2017 for the index patient's CD4+ T lymphocytes from 199 peripheral blood. From the paired sequencing we received 15,847 CD4+ T lymphocytes passing the quality 200 control, and they could be divided into nine distinct phenotypes with graph-based clustering. Interestingly, 201 most of the cells (72.0%) were characterized by cytotoxicity (clusters 0, 1, 2 and 3), and lower frequency of 202 naïve cells (20.8%, clusters 4 and 5) and regulatory T cells (3.2%, cluster 8) were identified (Figure 4 A-C). 203
The frequency of cells in clusters were stable between the time points indicating resistance to the ongoing 204 immunosuppressive treatment, and only the two smallest populations showed over two-fold-change 205 between the two timepoints (clusters 3 and 7, Figure S5 in the Supplementary Appendix). 206
From the TCRab-seq we detected TCRab, TCRa or TCRb from 11,055 cells (71.4%), resulting in 3651 unique 207 T cell clonotypes. The clonotype matching to TCRVB sequencing data ( Figure 1C ) and harboring the MTOR-208 mutation was also the most expanded fraction, representing 40.1% of the CD4+ T cells. Almost all of the 209 cells from this clonotype (90.1%) belonged to the cytotoxic clusters, and most of the cells were included in 210 the cluster 0 (74.6%) ( Figure 4D ). 211
To understand the effect of the MTOR-mutation on the T cells, we performed differential expression (DE) 212 analysis between the cytotoxic cells, comparing the cells from clonotype of interest against the other 213 cytotoxic cells in clusters 0, 1, 2 and 3. The analysis found 876 statistically significant DE-genes, of which 214 694 were upregulated in the clonotype, including cytotoxic genes (e.g. GZMA, GZMAB, GNLY, GZMK, NKG7 215 and PRF1), and HLA class I and II genes ( Figure 4E ). Additionally, upregulated eukaryote elongation factors 216 (eEFs), such as EEF1A1, EEF1B2, and EEF2, supported abnormal growth and proliferation of the expanded 217 CD4+ T cells. Furthermore, the expression of DUSP2 and KLRB1 genes was highly specific for the mutated 218 clone ( Figure 4B ). To identify differential pathway regulation in the clonotype, Gene Set Enrichment 219 Analysis (GSEA) was performed, resulting in 11 significantly over-represented and 0 under-represented 220 pathways in the clonotype (Table S11 in the Supplementary Appendix). The upregulated pathways included 221 MTORC1-pathway supporting the similar effect of the mutations in patient cells as observed in the in vitro 222 cell line models ( Figure 4F ). Other pathways found in the GSEA analyses included TNF-alpha signaling, IFNg 223 response and IL2-STAT5 signaling. 224
Real-time cytotoxicity analysis of CD4+ T cells against primary fibroblasts from the index patient 225
Real-time electrical impedance measurements monitoring target cell killing have been widely applied to 226 study the cellular cytotoxicity in vitro. (16, 17) To test the functional effects of the mutated CD4+ T cells and 227 to verify aberrantly upregulated gene expression signatures associated with cytotoxicity, we performed co-228 culture experiments with CD4+ T cells and primary fibroblasts. Addition of purified CD4+ T cells on the 229 mono-layer of primary fibroblasts from the index patient resulted in decreased electrical impedance 230 implicating cytotoxicity of the CD4+ T cells ( Figure 5A and B). In contrast, the CD8+ T cells showed no 231 cytotoxic activity against the fibroblasts, as the impedance curve mirrored the control well without effector 232
cells. 233 234
Drug Sensitivity and Resistance Testing (DSRT) in CD4+ T cells from the Index Patient 235
To determine sensitivity of the mutated cells to targeted therapy, robust ex vivo DSRT with 527 drugs in 5 236 different concentrations (18) was performed on freshly isolated CD4+ T cells from the index patient, the 237 donor, and a healthy control ( Figure 6 ). In this screen, the index patient's CD4+ T cells were less sensitive to 238 mTOR/PI3K inhibitors as compared to the donor's CD4+ T cells ( Figures 6A and B ), although constitutive 239 PI3K/AKT/mTOR activity generally predicts rapalog sensitivity. Instead, we observed that heat shock 240 protein 90 (HSP90) inhibitors showed an increased killing effect on the index patient's CD4+ T cells as 241 compared to CD4+ T cells from the donor and healthy control (Figures 6A, C, and D). Interestingly, scRNA-242 seq analysis indicated that one of HSP90 family members, HSP90AB1, was significantly upregulated in the 243 expanded CD4+ T cell clonotype, and it was one of the gene expression markers for the clonotype ( were sensitive to HDAC inhibitors, CDK-inhibitors, and proteosome inhibitors. The donor cells were also 246 modestly more sensitive to glucocorticoids (dexamethasone and methylprednisone), but this was not 247 statistically significant. Neither donor nor recipient CD4+ T cells were sensitive to cyclophosphamide, 248 tacrolimus, or methotrexate. However, it should be taken into account that the assay read-out is cell death, 249 and lymphocytes were not activated nor actively proliferating during the experiment. 250
In both WT and mutant HEK293 cells, the HSP90 inhibitor ganetespib reduced AKT phosphorylation on 251 serine 473. As expected, AKT-phosphorylation appeared to be normal following sirolimus treatment as 252 rapalogs only inhibit mTORC1 activity ( Figures 6E and F) . Treatment with either drug resulted in decreased 253 levels of phosphorylated S6K1 in both mutant and WT cells ( Figure 6G ). Both drugs also led to a reduced 254 pS6 phosphorylation in CD4+ T-lymphocytes from the index patient and a healthy control (Figures 6H and 255 I), suggesting an inhibitory effect on mTORC1 activity. Likewise, the scRNA-seq data analysis supported that 256 MTORC1 pathway is upregulated in the clonally expanded cytotoxic CD4+ T cells from the index patient 257 (Table S11 in the Supplementary Appendix). AKT was more phosphorylated in the patient's CD4+ T cells as 258 compared to controls with a slight decrease in both samples upon treatment with ganetespib or sirolimus. 259 260
Discussion 261
By analyzing blood CD4+ and CD8+ T cells we discovered a recurrent somatic missense mutation in 262 MTOR in cGvHD patients. In the index patient, the mutation was limited to the expanded CD4+ T cell clone, 263 it persisted for years and was found in both blood and sclerodermatous skin lesion samples. Paired scRNA-264
and TCRab-seq verified that the majority of the expanded CD4+ T cells had upregulated expression of genes 265 associated with cytotoxicity and cellular proliferation. Furthermore, mutated CD4+ T cells possessed 266 cytotoxicity against patient's own primary fibroblasts. No mutations were discovered in the sibling donor 267 samples suggesting the mutations been formed after the allo-HSCT. Functional in-vitro studies indicate that 268 the MTOR mutation results in a gain-of-function alteration activating both mTORC1 and mTORC2 pathways. Inhibition of the PI3K/AKT/mTOR axis by targeting the mTORC1 complex with rapamycin has been used to 286 prevent and treat GvHD.(28) Based on our data, the MTOR P2229R mutation induces the activation of both 287 the mTORC1 and mTORC2 as noted by increased S6K and AKT phosphorylation. Additionally, scRNA-seq 288 analysis strongly supported that MTORC1 pathway is upregulated in the clonally expanded and cytotoxic 289
CD4+ T cells from the index patient. 290
In addition to MTOR, the mutation in the NFKB2 gene is also a putative driver due to the 291 importance of this signaling pathway in the immune system. NF-κB has been extensively described as one 292 of the main regulators of the inflammatory response and cancer pathogenesis, offering a promising target 293 in anti-inflammation and -cancer drug development.(29) Both p50/RelA-mediated canonical and p52/RelB-294 mediated non-canonical pathways are involved in NFκB activation. Phosphorylated NFκB2 (p100) is 295 associated with RelB and sequentially ubiquitinated at the C-terminus to form the p52/RelB complex, 296 which is translocating into nucleus and activating downstream target genes.(30) Therefore, p52 formation 297 in NFκB2 (p100) processing is a key step for the activation of the non-canonical NFκB pathway. Especially 298 two serine residues in the C-terminal domain of NFκB2 (p100), S866 and S870, are necessary for NFκB2 299 (p100) processing.(31) The index patient harbored NFkB2 (p100) P882Q somatic mutation located in the C-300 terminus, which has not been reported in the COSMIC before. This mutation leads to an increased p52 301 formation which potentially induces a hyper-activation of non-canonical NF-κB pathway contributing to 302 chronic inflammation in the index patient. 303
Unlike the discovered NFkB2 and MTOR mutations, the TLR2 W558L somatic mutation was 304 identified in both cGvHD patients and healthy controls. However, VAFs were significantly higher in cGvHD 305 patients as in healthy controls. TLR2 is one of the pathogen-associated molecular pattern recognition 306 receptors and regulators of innate immunity, and it is constitutively expressed on regulatory and memory 307 CD4+ T cells.(32) TCR activation by an anti-CD3 antibody has been shown to induce the overexpression of 308 TLR2 on naïve CD4+ T cells followed by activation of the MyD88-dependent NF-κB signaling cascade and 309 inflammatory gene expression in peripheral blood.(33) Thus, in combination with the NFkB2 and MTOR 310 mutations, the TLR2 W558L mutation may further enhance the activation of the NF-κB and inflammatory 311
pathways. 312
Single-cell RNA-seq analysis revealed that the clonally expanded CD4+ T cells had upregulated 313 gene expression signatures associated with cytotoxicity (GZMA, GZMB, GNLY and NKG7) and proliferation 314 (DUSP2, KLRB1, EEF1A1, EEF1B2, and EEF2). Furthermore, real-time impedance analysis indicated 315 cytotoxicity of CD4+ T cells from the index patient, whereas the CD8+ T cells had no effect. Although 316 cytotoxicity has not been considered as a typical CD4+ T cell function (34), cytotoxic potential of T helper 317 cells (CD4+CTL) has been recently described including a granzyme-mediated killing capability of target cells 318 has not yet been clearly described.(37) From the proliferation associated genes, DUSP2 (PAC-1) was one of 320 the hallmark genes associated with the mutated clonotype. It is known as one of the MAPK phosphatases, 321 which play an important role in deactivating MAPK. DUSP2 is shown to be up-regulated in T cell activation 322 associated with inflammation.(38) Murine knockout phenotype studies for DUSP2 presented reduced 323 cytokine production and protected from inflammatory arthritis. In the murine colitis model, DUSP2 324 Drug sensitivity testing with patient cells indicated a lower efficacy of mTOR/PI3K inhibitors 332 compared to the donor, suggesting a hyperactivation of mTOR pathway due to the mutation. However, the 333 effect of ongoing immunosuppressive treatment (mycophenolate) cannot be ruled out as it may also affect 334 mTOR signaling.(42) Since the mTOR pathway is hyperactivated in many different types of cancer and 335 autoimmune diseases, mTOR inhibitors have been developed and applied to prevent dysregulated mTOR 336 signaling.(43-46) Rapamycin and its analogs are highly specific mTOR inhibitors that form a complex with 337 FKBP2, which selectively binds to the FRB domain of mTOR, leading to targeted inhibition of mTORC1-338 mediated signaling pathways. Therefore, alternative therapeutic applications have been suggested for 339 additionally targeting the dysregulated mTORC2 signaling pathway. Initially, Zheng et al. indicated that the 340 kinase domain of mTOR is a more potent site for mTOR inhibition as it is necessary for both rapamycin- results HSP90 inhibitors could serve as a novel therapeutic approach in a subset of cGvHD patients. 359
In conclusion, novel MTOR, NFkB2, and TLR2 somatic mutations were discovered in an expanded 360 CD4+ T cell clone in a patient with cGvHD. The mutations persisted over time and induced activation of the 361 NF-kB and MTOR pathways. The MTOR mutation was found to be recurrent in other cGvHD patients. 362
Although the MTOR mutation frequency was low in the total cGvHD cohort, somatic mutations may also 363 exist in other genes, and similar small subgroups of cGvHD patients can be discovered warranting further 364 investigations. Our findings imply a novel mechanism for the aberrant, persistent T cell activation in cGvHD 365 and pave the way for potential novel individualized therapies. Table  378 S1. All patients provided written informed consents. Additionally, buffy coat samples from 54 healthy blood 379 donors were obtained from the Finnish Red Cross Blood Service. A peripheral blood sample from the index 380 patient's sibling donor was also obtained. 381
The study was performed in compliance with the principles of Helsinki declaration, and was approved by Isolated genomic DNAs was used for TCRB deep sequencing. Sequencing and data analysis was conducted 440
with ImmunoSEQ assay as previously described (Adaptive Biotechnologies, Seattle, WA).(58) 441
Immunopanel Sequencing 443
A customized NGS panel including exonic areas of 986 genes related to immunity and cancer was used to 444 screen for somatic mutations.(6) Genes included in the panel are provided in the Supplemental Table S2 . 445
Sequencing was done from both sorted CD4+ and CD8+ T cells. Bioinformatic analysis to identify and 446 annotate somatic variants was performed as previously described.(6, 24) 447 448
Validation of the Somatic MTOR Mutation by Capillary Sequencing Analysis 449
A specific primer set was designed using the Primer-Blast search (National Center for Biotechnology 450 Information: http://blast.ncbi.nlm.nih.gov/) to validate the somatic MTOR mutation (Supplementary Table  451 S3). Polymerase chain reaction (PCR) products were purified with the ExoSAP-IT (Affymetrix) followed by 452 Table S4 ). The coverage was over 100,000 X, and a 457 variant was called if variant base frequency was 0.5% of all reads covering a given a position. All variants 458
with the base quality frequency ratio (ratio of number of variant calls/ number of all bases and quality sum 459 of variant calls / quality sum of all bases at the position) ≥ 0.9 were considered as true somatic variants. A 460 detailed sequencing protocol and the bioinformatics pipeline used for data analysis are described in 461 Enrichment Kit (10x Genomics). Finally, the total cDNA and the TCR-enriched cDNA was subjected to 473 fragmentation, end repair and A-tailing, adaptor ligation, and sample index PCR (14 and 9 cycles, 474 respectively). The gene expression libraries were sequenced using an Illumina NovaSeq, S1 flowcell with 475 the following read length configuration: Read1=26, i7=8, i5=0, Read2=91. The TCR-enriched libraries were 476 sequenced using an Illumina HiSeq2500 in Rapid Run mode with the following read length configuration: 477
Read1=150, i7=8, i5=0, Read2=150. The raw data was processed using Cell Ranger 2.1.1. with GRCh38 as 478 the reference genome. 479
During secondary analysis, cells with fewer than 200 or more than 4000 genes, or more than 15% of the 480 counts from mitochondrially-encoded transcripts were excluded from the analysis. The remaining data was 481 log-normalized and scaled. To reduce the dimensionality of the data, we determined the highly variable 482 genes as the genes with the highest variance-mean ratio. Genes that had mean expression between 0.0125 483 and 3 on a log-transformed count scale and genes above 0.5 log(variance/mean) were counted as highly 484 variable, resulting in 764 genes. The T-cell receptor V-genes, mitochondrial genes and ribosomal genes (n = 485 113) were excluded from the results, resulting in a final list of 651 highly variable genes. 486
Clusters were identified using the graph-based community identification algorithm as implemented in the 487
Seurat-package(28). Prior to calculating cell-cell distances, PCA was performed on the 651 highly variable 488 genes on all the QC-positive cells, and the top 50 principal components were kept. To prevent 489 overclustering, the optimal number of clusters was determined by increasing the resolution 490 hyperparameter as a function of number of clusters until the first saturation plateau was achieved. The 491 robustness of these clusters was assessed by subsampling cells and doing the analysis iteratively and 492 visually inspecting the results of embedding and differentially expressed genes between the formed 493 clusters. Differential expression analysis was performed based on the t-test, as suggested by Robinson et 494 al(59). Clusters were annotated using canonical cell type markers as well as the differentially expressed 495
genes. 496
Gene Set Enrichment Analysis (GSEA) (software.broadinstitute.org/gsea/index.jsp) between the clonotype 497 and other cytotoxic cells was performed on genes that were detected at least in 0.1% of the cytotoxic cells 498 and had at least log fold-change of 0.01 between the clonotype and other cytotoxic CD4+ T cells. The gene 499 list was ordered based on the fold-change. Overlap with HALLMARK-category was assessed and the False 500 Discovery Rate (FDR) calculated while the number of permutations was 1000. 501
Clonotypes were identified based on the available information, and both total nucleotide level TCRa and 502
TCRb were used if found. Cells for which more than two recombinants were identified were excluded from 503 further analysis. 504
From the TCRab-seq we detected TCRab, TCRa or TCRb from 11,055 cells (71.38%), resulting in 3651 505 different T cell clonotypes. The clonotype harboring the MTOR-mutation was the most expanded, 506 compromising of 2366 cells (TRA:CLVGDIGNQGGKLIF; TRB:CAWSTGQANNSPLHF). However, we noticed that 507 the second most (TRB:CAWSTGQANNSPLHF, 1545 cells) and third most expanded (TRA:CLVGDIGNQGGKLIF, 508 598 cells) clonotypes had only one chain and as they matched to the most expanded clonotype, we treated 509 this as error coming from uncomplete sequencing and pooled the three most expanded clonotypes into 510 one. 511 512
Analysis of cellular cytotoxicity 513
Primary fibroblasts from the index patient were cultured based on previous method.(60) Briefly, skin 514 biopsy from the index patient were dissected in small pieces (approx. 2mm x 2mm) and transferred into 6-515 well plate in 500 µl of complete growth medium containing 20% FBS. 2-300µl of growth medium was 516 added for every 2 days to replace evaporated media. After one week, increase amount of media to 2 ml 517 and change the media every 3 days. Once cells were confluent in each well, cells were trypsinized and 518 passaged. were reached a plateau, CD4+ T cells, CD8+ T cells, and NK92 as an cellular cytotoxicity inducer (6.4 x 10 4 529 cells as a ratio of the fibroblast to the inducer is 1:8) for the fibroblast were added on the plate. CD4+ T 530 cells and CD8+ T cells were separated from MNCs with CD4+ or CD8+ magnetic beads (Miltenyi Biotec) and 531 sorted by AutoMACs® cell sorter (Miltenyi Biotec) according to the manufacturer's protocol. The real-time 532 impedance trace for the fibroblasts exposed to CD4+ T cells, CD8+ T cells, and NK-92 were monitored for 48 533 h. 534 535
Multiplexed Immunohistochemistry (mIHC) 536
Tissue blocks were cut in 3.5 µm sections. Slides were deparaffinized in xylene and rehydrated in graded 537 ethanol series and H2O. Heat-induced epitope retrieval (HIER) was carried out in 10 mM Tris-HCl -1 mM 538 EDTA buffer in +99°C for 20 min (PT Module, Thermo Fisher Scientific). Peroxide activity was blocked in 0.9% 539 H2O2 solution for 15 min, and protein block performed with 10% normal goat serum (TBS-NGS) for 15 min. vector. The primer sequences used for the site-directed mutagenesis are in the Supplemental Table S5 . 561 562 Establishing Stable Cell Lines 563 HEK293 cells were transfected using FuGENE HD transfection reagent (Promega) with either a wildtype or 564 P2229R MTOR expression vector (ratio of reagent to DNA is 3:1) following the manufacturer's instruction. 565
Neomycin resistant clones were selected after the cells were cultured with G418 (500 µg/mL) for 3 weeks. 566
The lentiviruses were produced by co-transfection of HEK293FT cells with NFkB2 (wildtype or P882Q 567 mutant) or TLR2 (wildtype or W558L mutant) lentiviral expression vectors, and psPAX2 lentiviral packaging 568 plasmid (Addgene) and pCMV-VSV-G envelope plasmid (Addgene) using Lipofectamine® 2000 (Thermo 569
Fisher Scientific). Antibiotic free DMEM containing 10% FBS was used as a culturing medium and Opti-MEM 570 I Reduced Serum Medium (Thermo Fisher Scientific) supplemented with 5% FBS and 1 mM Sodium 571 pyruvate was used as a lentivirus packaging medium. 6 hours post-transfection, medium was removed and 572 replaced with DMEM. After 48 hours, the supernatants were centrifuged at 300 g for 5 min to remove cell 573 debris and filtered with a 0.45 µm polyethersulfone membrane filter. Ultracentrifugation to concentrate 574 the virus was performed for 2 hours at 12,000 g and 4°C using Beckman SW28 rotor. Lentivirus titers were 575 measured by p24 specific enzyme-linked immunosorbent assay. 576 577
Establishment of Triple Mutant Stable Cell Lines 578
HEK293 cells stably expressing exogenous MTOR (wildtype or P2229R mutant) were transduced with NFkB2 579 (wild type or P882Q mutant) expressing lentiviruses. Infections were performed in the presence of 8 µg 580 /mL of polybrene under centrifugation (500 g, 37°C) for 2 hours. MTOR-NFkB2 transduced cells (expressing 581 Cyan Fluorescent Protein) were selected by using FACsAriaIII (BD Biosciences). Cells expressing exogenous 582 MTOR-NFkB2 (wildtype or mutant) were infected with TLR2 (wildtype or W558L mutant) expressing 583 lentiviruses as described above and selected using puromycin (3 µg/mL). 584 585
Western Blot Analysis 586
After removing serum containing medium, HEK293 cells were washed twice with ice-cold PBS followed by 587 serum starvation for 12 hours. Cells were then harvested and further lysed in ice-cold RIPA buffer with 1X 588 protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific). To remove cell debris, 589 centrifugation was carried out for 10 min at 4 °C, 12,000 g. Total protein concentration was measured with 590 the Qubit protein assay (Thermo Fisher Scientific) and 5 µg of protein per sample was prepared in Laemmil 591 buffer (Bio-Rad Laboratories) to load on a SDS-PAGE gel (Bio-Rad Laboratories). After running the sample in 592 the SDS-PAGE gel, the proteins were transferred into a nitrocellulose membrane (Merk Millipore) followed 593 by blocking the membrane with Odyssey blocking buffer (LI-COR Biosciences) for 1 hour. Primary 594 antibodies (1:1000 dilution) were incubated overnight at 4°C in PBS with 0.1% Tween 20 containing 5% milk, 595 and subsequently secondary antibodies (1:15,000 dilution) in PBS with 0.1% Tween 20 containing 5% milk 596 were incubated for 1 hour at room temperature. The proteins were visualized using Odyssey Imaging 597 Systems (LI-COR Biosciences). 598 599
Drug Sensitivity and Resistance Testing (DSRT) 600
Ex-vivo DSRT was performed on freshly isolated CD4+ T cells with a total of 527 drugs in 5 concentrations 601 covering a 10,000-fold concentration range including conventional chemotherapeutics and a broad range 602 of targeted oncology compounds.(47) To dissolve the drug compounds, 5 µl of medium was dispensed into 603 each well of 384 well plates including five different concentrations of each drug. 20 µl of cell suspension 604 (CD4+ T cells from healthy control, donor and index patient: 2,000 cells per well) was transferred to every 605 well using MultiFlo FX dispenser (BioTek). After incubation (5% CO2 at 37°C) for 72 hours, the cell viability 606 was evaluated by CellTiter-Glo Assay solution (Promega). The drug sensitivity score (DSS) was calculated to 607 evaluate quantitative drug profiles based on the measured dose-response curve.(61) 608 609 610
Reverse Transcriptase-quantitative Polymerase Chain Reaction (RT-qPCR) 611 612
Total RNA was extracted using the RNeasy Mini kit (Qiagen) followed by cDNA synthesis using QuantiNova 613
Reverse Transcription kit (Qiagen) according to the manufacturer's protocol. The cDNA was applied in SYBR 614
Green RT-PCR master mix (Applied Biosystems) and oligonucleotide primers ( Supplementary Table S6 ). All 615 RT-qPCR reactions were performed in 384-microwell plates (Applied Biosystem) using a QuantStudio 6 Flex 616
Real-Time PCR system (Applied Biosystems). The relative quantitation of gene expression was analyzed 617 using comparative cycle threshold (ΔΔCT) method, and beta actin (ACTB) was used as an endogenous 618 control to normalize gene expression level. 619 620
Data availability 621
Patient whole-exome and RNA-sequencing raw data related to table 1 and figure 4 are available from the 622 corresponding author upon request owing to regulations pertaining to the authors ethics permit and 623 deposition of these data in public repositories. 624 625
Statistical Analysis 626
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